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Abstract
Background: The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) is
strongly associated with activating EGFR mutations. Although not as sensitive as patients harboring these mutations, some
patients with wild-type EGFR (wtEGFR) remain responsive to EGFR TKIs, suggesting that the existence of unexplored
mechanisms renders most of wtEGFR-expressing cancer cells insensitive.
Methodology/Principal Findings: Here, we show that acquired resistance of wtEGFR-expressing cancer cells to an EGFR TKI,
gefitinib, is associated with elevated expression of breast cancer resistance protein (BCRP/ABCG2), which in turn leads to
gefitinib efflux from cells. In addition, BCRP/ABCG2 expression correlates with poor response to gefitinib in both cancer cell
lines and lung cancer patients with wtEGFR. Co-treatment with BCRP/ABCG2 inhibitors enhanced the anti-tumor activity of
gefitinib.
Conclusions/Significance: Thus, BCRP/ABCG2 expression may be a predictor for poor efficacy of gefitinib treatment, and
targeting BCRP/ABCG2 may broaden the use of gefitinib in patients with wtEGFR.
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Introduction
The oncogenic EGFR tyrosine kinase, commonly overexpressed
in a variety of solid tumors, plays important roles in cancer aetiology
and progression, and thus is a rational target for cancer therapies.
Selective small molecular inhibitors of EGFR tyrosine kinase
(EGFR TKIs) have shown promising clinical activity in the last
decade. Moreover, clinical studies reported that treatment of
selectiveEGFR TKIsasmonotherapy,includinggefitinib(ZD1839,
Iressa) and erlotinib (OSI-774, Tarceva), leads to tumor regression
in 12–27% of advanced NSCLC patients [1,2,3].
Encouraging response to gefitinib is frequently observed in East
Asian, female, adenocarcinoma histology, and non-smoking
patients, and is closely associated with specific activating mutations
in EGFR tyrosine kinase domain [4,5,6]. Since only a small
population of unselected NSCLC patients has these mutations
(about 10–15%), the clinical use of gefitinib is somewhat limited
[4,5,6]. Nevertheless, 20–30% of NSCLC patients with amplified
wild-type EGFR (wtEGFR) still demonstrated significant survival
benefits from gefitinib and erlotinib treatment even though they
showed lower response rate compared with patients with EGFR
mutations [7,8,9]. Moreover, approximately 10–20% of gefitinib-
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mutations [6,7,8,10,11,12,13], suggesting that other unknown
mechanisms may also contribute to the resistance to TKI
treatment for most of patients with amplified wtEGFR. Therefore,
the sensitivity to EGFR TKIs may not be determined only by
these EGFR activating mutations.
To broaden the clinical use of EGFR TKIs, it is critical and timely
to identify the determinants which render majority of wtEGFR-
expressing cancer cells resistant to these drugs. Notably, a case report
showed that a non-smoking female NSCLC patient with wtEGFR
expression was initially responsive to gefitinib but ultimately
developed acquired resistance without any detectable EGFR
mutation. Interestingly, the expression of breast cancer resistance
protein (BCRP/ABCG2), a well-known transporter of ATP-binding
cassette (ABC) family involved in chemo-resistance [14,15], was
detected in the recurrent tumor from this patient [16]. Studies have
shown that gefitinib not only acts as an inhibitor but also as a
substrate for BCRP/ABCG2 [17,18,19], and enforced expression of
BCRP/ABCG2 reduced the sensitivity of wtEGFR-expressing A431
cells to gefitinib [20]. Although these findings suggest a potential role
of BCRP/ABCG2 in influencing the sensitivity to gefitinib, it remains
unclear whether BCRP/ABCG2 expression is affected by gefitinib
treatment and thus contributes to the resistance to this inhibitor.
In this study, acquisition of BCRP/ABCG2 expression was
observed in wtEGFR-expressing and gefitinib-sensitive A431 cells
after chronic treatment with gefitinib. Inhibition of BCRP/
ABCG2 reduced gefitinib efflux and re-sensitized the cell line to
this drug. The clinical correlation between BCRP/ABCG2
expression in tumor lesions and poor outcome was also observed
in wtEGFR-expressing NSCLC patients who received gefitinib
treatment. Our findings suggest that BCRP/ABCG2 expression
may be a predictive factor for the sensitivity to gefitinib in patients
with amplified wtEGFR and also a potential target for increasing
the sensitivity to this inhibitor.
Results
BCRP/ABCG2 expression is elevated in acquired
gefitinib-resistant A431/GR cells
In this study, we employed wtEGFR-expressing and gefitinib-
sensitive A431 epidermoid cell line and its gefitinib-resistant
derivative, A431/GR [21] to address whether BCRP/ABCG2
plays a role in determining EGFR-TKI sensitivity in wtEGFR-
expressing cancer cells. EGFR expression in the A431/GR cells
retained the wild-type status as examined by cDNA sequencing
(data not shown). In A431/GR cells, both mRNA (Figs. 1A and B)
Figure 1. Acquired gefitinib-resistance in A431/GR cells induces BCRP/ABCG2 expression. A–B, The mRNA expression levels of BCRP/
ABCG2, MDR1/ABCB1, and MRP1/ABCC1 in A431 and A431/GR cells were analyzed by RT-PCR (A) and the increased folds of BCRP/ABCG2 mRNA was
measured by real-time PCR (B). Error bars in (B) denote s.e.m. (n=3). Fold change of BCRP/ABCG2 mRNA expression was quantitated relative to the
internal control, b-actin. C, The BCRP/ABCG2 protein expression level was analyzed by Western blot. D, A431 cells were treated with 1 mM gefitinib for
the indicated time points, and cell extracts were analyzed by immunoblotting for BCRP/ABCG2 protein expression. The fold change of BCRP/ABCG2
protein expression was quantitated relative to the internal control, a-tubulin.
doi:10.1371/journal.pone.0021428.g001
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elevated as compared with that in parental A431 cells. However,
the mRNA expression of multi-drug resistance 1 (MDR1)/ABCB1
and multi-drug resistance-related protein 1 (MRP1)/ABCC1, two
other well-known ABC transporters related to chemo-resistance
[14,15], were not increased in response to gefitinib-resistance
(Fig. 1A). In support of the results from A431/GR cells, the
induction of BCRP/ABCG2 was also observed in parental A431
cells after treatment with gefitinib for 2 weeks, and continued for at
least 6 weeks (Fig. 1D). Moreover, the elevation of BCRP/ABCG2
expression remained sustained even 7 days after gefitinib was
removed from the culture medium of A431/GR cells (Fig. S1A).
In parallel to this result, A431/GR cells cultured in gefitinib-free
medium for 7 days still show the resistant phenotype as compared
to those cultured in gefitinib-containing medium (Fig. S1B). These
results suggest that the induction of BCRP/ABCG2 expression
may not be reversible upon the withdrawal of gefitinib and reveal
that BCRP/ABCG2 expression was specifically and irreversibly
increased by gefitinib treatment, raising the possibility of the
involvement of BCRP/ABCG2 in conferring acquired resistance
to gefitinib.
The gefitinib efflux in A431/GR cells is mediated by BCRP/
ABCG2
Since gefitinib serves as both a substrate and an inhibitor for
BCRP/ABCG2 [17,18,19], we further examined whether gefitinib
is able to sustainably inhibit EGFR activity in A431/GR cells by
detecting phosphorylation of EGFR Tyr1068 as an indicator. To
this end, A431 and A431/GR cells were first cultured without
gefitinib for 24 hrs and then treated with or without 0.1 mM
gefitinib for indicated periods of time followed by EGF treatment
for 10 minutes. As shown in Fig. 2A, gefitinib persistently inhibited
the EGF-induced EGFR phosphorylation for at least 24 hrs in
A431 cells. But the inhibitory effect of gefitinib on EGFR
phosphorylation in A431/GR cells was partial and transient for
up to 6 hrs, and this inhibitory effect was not observed if the
pretreatment with gefitinib was over 10 hrs (Fig. 2A and Fig. S2).
These observations imply that, in the presence of BCRP/ABCG2
expression, gefitinib transient inhibition of EGFR activity in
A431/GR cells is probably due to a rapid efflux of this drug. In
support of this notion, the transient inhibition of EGFR activity in
A431/GR cells was prolonged when the concentration of gefitinib
was increased (Fig. S2).
To further demonstrate that the transient EGFR inhibition by
gefitinib in A431/GR cells was due to drug efflux, both A431 and
A431/GR cells were treated first with gefitinib for 1 hr, and after
incubation, the medium was removed and cells were replenished
with fresh medium without the drug to allow recovery for another
hour (as illustrated in Fig. 2B, left). After the 1 hr after incubation/
recovery time, we collected the medium from parental A431 and
A431/GR cells (hereafter referred to as the ‘‘conditioned
medium’’) and prepared cell extracts for Western blot analysis of
EGFR activity. In A431/GR cells, EGFR Tyr1068 phosphoryla-
tion was recovered from the inhibition by gefitinib after the drug
was removed and medium refreshed for 1 hr (Fig. 2B, top right,
lanes 5 and 6) but not in the parental A431 cells (Fig. 2B, top right,
lanes 2 and 3). We hypothesized that the reduction in the
inhibition of EGFR Tyr1068 phosphorylation in A431/GR cells
might be associated with gefitinib efflux, and therefore, the anti-
EGFR tyrosine kinase activity of the conditioned medium from
A431/GR cells would be higher than that of the parental A431
cells. To test this hypothesis, EGFR-overexpressing MDA-MB-468
breast cancer cells were treated with the conditioned medium
collected as described above. We found that the conditioned
medium from A431/GR cells significantly inhibited EGFR
Tyr1068 phosphorylation in MDA-MB-468 cells (Fig. 2B, bottom
right, lanes 5 and 6). In contrast, the conditioned medium from the
parental A431 cells did not affect Tyr1068 phosphorylation of
EGFR in MDA-MB-468 cells (Fig. 2B, bottom right, lanes 2 and
3). These results show that gefitinib is active in the A431/GR cells
temporarily during the first 1-hr incubation but is then pumped
out of the cell into the medium during the second 1-hr incubation
with fresh medium, suggesting that gefitinib might be pumped out
of the resistant cells much more easily than the sensitive cells.
Next, we examined whether blockage of BCRP/ABCG2
reduces the efflux of gefitinib in A431/GR cells. To this end,
shRNA and inhibitors of BCRP/ABCG2 were used to block
BCRP/ABCG2 function. As shown in Fig. 2C, inhibition of
EGFR Tyr1068 phosphorylation by gefitinib was recovered within
24 hr in the control cells (Fig. 2C, lanes 1–3). However, silencing
of BCRP/ABCG2 expression by shRNA reduced the recovery of
EGFR Tyr1068 phosphorylation inhibited by gefitinib (Fig. 2C,
lanes 4–6). Consistent with this finding, the inhibitory effect of
gefitinib on EGFR activity in A431/GR cells was also enhanced in
the presence of chrysin or benzoflavone (Figs. 2D and E), two well-
established BCRP/ABCG2 inhibitors [22,23,24]. The percentage
of EGFR Tyr1068 phosphorylation under BCRP/ABCG2
shRNA, chrysin, or benzoflavone treatment is shown (Figs. 2C–
E; bottom panels). These results suggest that BCRP/ABCG2
expression is increased in the gefitinib-resistant cells, and thus
facilitates the efflux of gefitinib.
Blockage of BCRP/ABCG2 re-sensitizes A431/GR cells to
gefitinib treatment
From the results above, inhibition of BCRP/ABCG2 activity
may be able to reduce the acquired resistance to gefitinib by
preventing the drug efflux. We further examined the cytostatic
effect of gefitinib in A431/GR cells in the presence of BCRP/
ABCG2 shRNA or BCRP/ABCG2 inhibitors. As expected, both
silencing BCRP/ABCG2 (Fig. 3A) and treatment of chrysin or
benzoflavone (Fig. 3B) significantly enhanced gefitinib-mediated
cytostatic effect in A431/GR cells. However, these effects were not
as obvious in A431 parental cells. Finally, a combined treatment
with chrysin also enhanced gefitinib-mediated tumor regression in
the A431/GR xenograft mouse model (Fig. 3C, left). EGFR
activity was indeed reduced in the A431/GR-xenograft tumors
treated with both chrysin and gefitinib but not in those treated
with gefitinib or chrysin alone (Fig. 3C, right), supporting that co-
targeting BCRP/ABCG2 may circumvent acquired gefitinib
resistance both in vitro and in vivo.
BCRP/ABCG2 expression is involved in intrinsic resistance
to gefitinib
Next, to further strengthen the role of BCRP/ABCG2 in
influencing gefitinib sensitivity, the correlation between BCRP/
ABCG2 expression and gefitinib sensitivity was evaluated in
various lung cancer cell lines, which express either wild-type or
mutated EGFR [25,26]. As shown in Fig. 4A, the BCRP/ABCG2
expression was only detected in the gefitinib-insensitive lung
cancer cells bearing wtEGFR (A549). In contrast, neither gefitinib-
sensitive nor gefitinib-resistant lung cancer cells carrying EGFR
mutants showed BCRP/ABCG2 expression. In addition to lung
cancer cells, head and neck cancer cells also frequently overexpress
wtEGFR, but very few are sensitive to gefitinib. We found that two
of five gefitinib-resistant head and neck cancer cell lines [27],
including FaDu, and OECM-1 cell lines, express significant levels
of BCRP/ABCG2 protein but was not detected in two gefitinib-
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21428Figure 2. BCRP/ABCG2 shRNA and inhibitors reduce gefitinib efflux in A431/GR cells. A, A431 and A431/GR cells were cultured without
gefitinib for 24 hr and then treated with DMSO or 0.1 mM gefitinib for the indicated period of time followed by 50 ng/ml EGF treatment for 10
minutes. Whole cell lysates were harvested and EGFR Tyr1068 phosphorylation was analyzed by Western blot (left) and quantitated (right). B, A431
and A431/GR cells were treated first with 5 mM gefitinib for 1 hr, and after incubation, the medium was removed and cells were replenished with
fresh medium without the drug to allow recovery. After an hour incubation/recovery in the absence of gefitinib, the conditioned medium was
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FaDu cells were co-treated with BCRP/ABCG2 inhibitor
benzoflavone, their sensitivity to gefitinib was significantly
increased (Figs. 4C and D, respectively). These results imply that
the intrinsic insensitivity of these cell lines to gefitinib might be, at
least in part, due to the expression of BCRP/ABCG2.
To further validate the clinical relevance between BCRP/
ABCG2 expression and intrinsic gefitinib resistance, lung tumor
specimens from forty-nine patients (Table S1) were examined to
identify the correlation between membrane BCRP/ABCG2
expression and the clinical benefit from gefitinib treatment.
Although the association between membrane BCRP/ABCG2
Figure 3. Inhibition of BCRP/ABCG2 overcomes the acquired resistance to gefitinib in A431/GR cells. A–B, The effect of BCRP/ABCG2
shRNA virus (A) or BCRP/ABCG2 inhibitors (B) on gefitinib sensitivity in A431/GR cells was measured by MTT assay. C, The effect of co-treatment of
BCRP/ABCG2 inhibitor chrysin on the anti-tumor activity of gefitinib was examined in A431/GR-xenograft mouse model. After treatment of the
indicated drug for 30 days, mice were sacrificed and tumors were weighed and measured (left). The xenograft tumor tissues from each group were
homogenized and the total lysate were subjected to immunoblotting analysis with indicated antibodies (right). Error bars in A and B denote s.e.m.
(n=3). *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0021428.g003
collected and extracts were prepared to examine the recovery of EGFR activity by Western blot analysis (upper right). To test for presence of gefitinib
efflux, MDA-MB-468 breast cancer cells were subjected to the conditioned medium (C.M.) collected from parental A431 and A431/GR cells after 1 hr
incubation/recovery time. The effect of the conditioned medium on EGF-induced EGFR activity in MDA-MB-468 cells was further examined by
Western blot (lower right). The detailed procedure is shown on the left. C-E, The recovery of EGFR activity from gefitinib inhibition in A431/GR cells
infected with BCRP/ABCG2 shRNA virus (C) or treated with BCRP/ABCG2 inhibitors (D and E) was measured as described in Fig. 2B, left. Intensity was
quantitated relative to the individual total EGFR expression (bottom).
doi:10.1371/journal.pone.0021428.g002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21428Figure 4. BCRP/ABCG2 expression is involved in intrinsic resistance to gefitinib. A–B, Western blot analysis of EGFR and BCRP/ABCG2
protein expression in lung (A) and head and neck (B) cancer cell lines bearing either wild-type or mutant EGFR. ‘‘S’’ and ‘‘R’’ represent gefitinib-
sensitive and -resistant, respectively. C–D, The effect of gefitinib on cell viability of A549 (gefitinib-resistant; C) and FaDu (gefitinib-resistant; D) cells in
the absence or presence of benzoflavone, a BCRP/ABCG2 inhibitor, was measured by MTT assay. Error bars in C and D denote s.e.m. (n=3). *, p,0.05;
Gefitinib Resistance by ABCG2-Mediated Efflux
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statistical significance, the group with negative membrane BCRP/
ABCG2 expression showed a higher percentage of stable disease
and partial response (Table S2). Nevertheless, both progression
free survival (PFS) and overall survival (OS) rates of these gefitinib-
treated patients, as shown in Figs. 4E and F respectively, were
significantly inversely associated with membrane BCRP/ABCG2
expression, indicating that patients with low membrane BCRP/
ABCG2 expression may receive better survival benefit from
gefitinib therapy. Together, our results suggest that membrane
BCRP/ABCG2 expression may be another valuable marker to
predict the clinical outcome of gefitinib-treated patients without
EGFR activating mutations, and co-treatment with BCRP/
ABCG2 inhibitors may increase the sensitivity to gefitinib and
broaden its clinical use.
Discussion
While the development of secondary EGFR mutations [5,26]
and alternative survival signals from other growth receptor
activations such as c-Met [28,29] have been widely known for
conferring acquired gefitinib resistance of NSCLC patients who
express activating EGFR mutations, very few related studies have
reported the use of wtEGFR-expressing cells as the study model
[21]. Here, we utilized a pair of epidermoid cancer cell lines
expressing wtEGFR in an identical genetic background as a model
to explore the determinants and the underlying mechanisms of
acquired gefitinib resistance. Previously, it has been reported that
BCRP/ABCG2 expression can be detected in a wtEGFR-
expressing patient with acquired gefitinib resistance [16]. In the
current study, we further validated this observation and showed
that BCRP/ABCG2 expression, but not MDR1/ABCB1 and
MRP1/ABCC1 expression, was indeed induced by chronic
treatment of gefitinib in wtEGFR-expressing A431 cells (Fig. 1A)
but not in mutEGFR-expressing PC-9 cells (Fig. 4A, PC-9 v.s. PC-
9-GR). It was recently demonstrated that the BCRP/ABCG2
expression in the A431/GR cells is mediated by the Akt-
dependent nuclear import of EGFR [30]. The induced BCRP/
ABCG2 caused an efflux of gefitinib from the resistant but not
sensitive A431 cancer cells. Therefore, co-targeting BCRP/
ABCG2 can overcome the acquired gefitinib resistance both in
vitro and in vivo. Although EGFR TKIs have been shown to serve as
substrates of BCRP/ABCG2 [17,18,19], they have also been
reported to be inhibitors of BCRP/ABCG2 [31,32]. The
molecular pathway that is described here provides a logical
interpretation for the dual roles of gefitinib. The cross-resistance of
A431/GR cells to erlotinib has previously been reported [21].
However, re-sensitization of A431/GR cells to erlotinib was not
observed by using BCRP/ABCG2 inhibitor or shRNA (Figs S3A–
C). Similar to our findings, co-treatment with other BCRP/
ABCG2 inhibitors also had no effect on erlotinib activity in colon
cancer cell lines, which might be due to the fact that erlotinib is not
recognized as a typical substrate by BCRP/ABCG2 [31].
Therefore, BCRP/ABCG2 does not seem to be the major
determinant of the cross-resistance to erlotinib in the cell model
used in this study, and other mechanisms remain to be clarified.
Since BCRP/ABCG2-positive tumors were found in 46% of
advanced NSCLC patients [33], the BCRP/ABCG2-dependent
drug resistance to gefitinib but not erlotinib might explain why
erlotinib provides a better clinical outcome than gefitinib [7,8] and
may serve as a salvage treatment for NSCLC patients after failure
of gefitinib treatment [34,35]. In addition to BCRP/ABCG2,
gefitinib and other TKIs have also been reported to function as
inhibitors, but not substrates, of MDR1/ABCB1 [19,32,36,37],
another important ABC transporter for chemotherapeutic agents,
indicating that MDR1/ABCB1 may be a potential target of TKIs
to overcome chemoresistance rather than contributing to the drug
resistance to these EGFR TKIs. However, we still cannot exclude
the possibility that other members of ABC transporter family are
involved in TKI resistance.
In addition to the gefitinib resistance, the increased expression
of BCRP/ABCG2 also caused A431/GR cells to become cross-
resistant to the chemotherapeutic agent doxorubicin, a well-
established typical BCRP/ABCG2 substrate (Fig. S4A). The cross-
resistance of A431/GR cells to doxorubicin can be reversed by
benzoflavone (Fig. S4B). This finding suggests that BCRP/
ABCG2-mediated drug efflux may be a common mechanism in
gefitinib resistance and chemo-resistance, and raises an important
issue of the timing in the use of gefitinib, a second-line therapeutic
option originally approved by the U.S. FDA for advanced NSCLC
patients who have failed systemic chemotherapy. Although a close
association between prior chemotherapy and membrane BCRP/
ABCG2 was not obtained in our current data due to the limited
number of patients for the analysis of the impact of various types of
chemotherapy on BCRP/ABCG2 induction (Table S3), expres-
sion of BCRP/ABCG2 has been found in several chemotherapy-
resistant tumors [38,39] and is correlated with the poor clinical
outcome to platinum-based chemotherapy [33]. The BCRP/
ABCG2-mediated gefitinib efflux may account for the poor
clinical outcomes in most of the chemo-resistant patients while
using gefitinib as second- or third-line therapy since results from
several clinical trials revealed that the gefitinib response rate is
higher in chemonaive than in chemotherapy-treated patients
[40,41,42]. Our data also suggest that the membrane BCRP/
ABCG2-negative patients have better survival benefits (Figs. 4E
and F) and a higher response rate trend (Table S2) from gefitinib
treatment than membrane BCRP/ABCG2-positive patients.
As the field of medicine moves toward an era of personalization,
treatment decisions require the inputs of tumor-specific informa-
tion. Our findings suggest that, in addition to the EGFR
mutations, the status of BCRP/ABCG2 may also impact the
effectiveness of gefitinib. Using BCRP/ABCG2 as another
predictor of the clinical response to gefitinib will help us to decide
on the use and priority of anti-cancer therapies. Our results also
indicate that co-targeting BCRP/ABCG2 may not only overcome
gefitinib resistance but also broaden the clinical use of gefitinib for
various cancers with wtEGFR. Since intrinsic resistance was also
observed in BCRP/ABCG2-negative cancer cells (Figs. 4A and B),
the BCRP/ABCG2-mediated drug efflux may not be the only
mechanism contributing to insensitivity of wtEGFR-expressing
cancer cells to gefitinib, and other mechanisms await to be
explored.
Materials and Methods
Cell lines and reagents
A431 and A431/GR cell lines were gifts from Dr. Carlos L.
Arteaga (Vanderbilt-Ingram Cancer Center, Nashville, TN).
Acquired gefitinib resistant cancer cells (A431/GR) were cultured
in the presence of 1 mM gefitinib as described previously [21].
**, p,0.01; ***, p,0.001. E–F, Progression-free survival (E) and overall survival (F) rates of membrane BCRP/ABCG2-positive or -negative lung cancer
patients who received gefitinib therapy were analyzed as described in the ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0021428.g004
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from the pharmacy of The University of Texas MD Anderson
Cancer Center for both in vitro and in vivo experiments described in
this study. Epidermal growth factor (EGF), chrysin, and benzo-
flavone were purchased from Sigma-Aldrich (St. Louis, MO).
Anti-EGFR (SC-03) antibody from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA) was used for EGFR immunoblotting. To
detect EGFR autophosphorylation, a site-specific antibody against
phospho-Y1068 from Cell Signaling (Danvers, MA) was used.
BCRP/ABCG2 protein level was detected by anti-BCRP/ABCG2
antibody from Santa Cruz (SC58222) and by immunohistochem-
istry using anti-BCRP/ABCG2 antibody (MAB4146) from
Chemicon (Billerica, MA).
shRNA infection
BCRP/ABCG2 shRNA clones were purchased from the
National RNAi Core Facility at Academia Sinica (Taipei, Taiwan).
BCRP/ABCG2 shRNA virus packaging was prepared according to
the manufacturer’s instruction, and the BCRP/ABCG2 shRNA
virus was used to infect target cells. Briefly, cells (8610
3 cells per
well) were seeded in 96-well plates, and 24 hr after seeding, cells
were infected with BCRP/ABCG2 shRNA virus at MOI 150. The
next day, cells were refreshed with complete medium and then
subjected to further indicated experiments.
Cell proliferation assay
In vitro cell proliferation was carried out using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) col-
orimetric assay. Briefly, cells (5–8610
3 cells per well) were seeded
in 96-well plates, and 24 hr after seeding, cells were subjected to
pre-treatments as indicated, including shRNA virus infection or
pre-treatment of BCRP/ABCG2 inhibitors. After treatment of
gefitinib, erlotinib, or doxorubicin for 48 or 72 hr, relative cell
amounts were determined by adding 1 mg/ml MTT to each well.
After a 3-hr incubation, the medium was removed, and MTT was
solubilized in 100 ml of dimethyl sulfoxide (DMSO). The
absorbance was measured at 570 nm.
Xenograft mouse model
All animal works were done in accordance with a protocol
approved by the Institutional Animal Care and Use Committee of
China Medical University and Hospital (No. 100-61-N). In vivo cell
growth was analyzed in an orthotopic epidermoid cancer mouse
model [21]. Briefly, A431/GR cells (5610
6 cells) were injected
subcutaneously into nude mice, and the tumor volumes were
measured weekly. Once the tumor size reached 40 mm
3, mice
were subjected to oral treatment with saline, gefitinib (20 mg/kg),
chrysin (100 mg/kg), or gefitinib (20 mg/kg) plus chrysin
(100 mg/kg) every day. One month later, all mice were sacrificed
and tumor size was weighed. The tumor weight was analyzed by a
two-sided t-test.
Immunohistochemical staining (IHC) of human lung
tumor tissues
IHC was performed using anti-BCRP/ABCG2 antibodies
(MAB4146, Chemicon). Briefly, the biotin-conjugated secondary
antibody was incubated to form avidin-biotin-peroxidase complex.
The immunoreaction was visualized by using aminoethylcarbazole
chromogen as substrate. Protein staining was evaluated on a dual
semi-quantitative scale combining staining intensity and percent-
age of positive cells in the cancer fields. The IHC score .0o r=0
was defined respectively as positive or negative for membrane
BCRP/ABCG2 expression. Two investigators, independently and
in a blind fashion, analyzed the protein expression. Fisher’s exact
and Spearman rank correlation tests were used for statistical
analysis; p,0.05 was considered statistically significant. Lung
cancer tumor tissues were collected from patients who received
surgery at The University of Texas MD Anderson Cancer Center
(Houston, TX). In both cancerous and non-cancerous sections, the
fresh frozen tissue (stored in liquid nitrogen) and tissue embedded
in paraffin were used for histology. All patients have signed the
informed consent according to the IRB-approved protocol.
Statistical analysis
Fisher exact test was used to test differences of category
variables. The distribution of overall survival (OS) and progres-
sion-free survival (PFS) were estimated by the Kaplan-Meier
method [43]. Log-rank test was performed to test the difference in
survival between groups. Regression analyses of survival data
based on the Cox proportional hazards model were conducted on
PFS defined from the time of the start of gefitinib treatment to the
time of progression or to the time of last contact, and OS was
defined from the time of the start of gefitinib to the time of death
or to the time of last contact. SAS version 9.1 and S-Plus version
7.0 were used to carry out the computations for all analyses.
Supporting Information
Figure S1 BCRP/ABCG2 expression and gefitinib resis-
tance in A431/GR cells were sustained upon gefitinib
withdrawal. A, A431/GR cells were cultured in 1 mM gefitinib-
containing medium. After 24 hrs of subculture, gefitinib was
removed followed by collection of whole cell lysates on indicated
days and then subjected to immunoblotting analysis with anti-
BCRP and anti-tubulin antibodies. B, A431/GR cells were
maintained with complete medium in the absence or presence of
1 mM gefitinib for 7 days and then subcultured with gefitinib-free
medium and seeded in 96-well plate for viability assay. After
24 hrs of subculture, culture medium was refreshed and added
with different concentrations of gefitinib for another 3 days. The
cytostatic effect of gefitinib was measured by MTT assay.
(DOC)
Figure S2 Transient inhibitory effect of gefitinib was
observed in A431/GR cells. A431/GR cells were cultured
without gefitinib for 24 hrs. A431/GR cells were treated with 0.1,
0.5, and 1 mM gefitinib as indicated periods of time followed by
50 ng/ml EGF treatment for 10 minutes. EGFR Tyr1068
phosphorylation in A431/GR cells was analyzed by Western blot
(top) and quantitated (bottom).
(DOC)
Figure S3 BCRP/ABCG2 inhibition did not restore the
cytostatic effect of erlotinib in A431/GR cells. A–B, Effects
of benzoflavone (A) and BCRP/ABCG2 shRNA (B) on erlotinib
cytostatic activity in A431/GR cells were examined by MTT
assay. C, Effect of BCRP/ABCG2 shRNA on the recovery of
EGFR activity from erlotinib inhibition was examined as
described in Fig. 2B. Error bars in A and B denote s.e.m. (n=3).
(DOC)
Figure S4 A431/GR cells were cross-resistant to doxo-
rubicin due to the expression of BCRP/ABCG2. A,
Sensitivity of A431 and A431/GR cells to doxorubicin was
measured by MTT assay. B, The effect of benzoflavone on
doxorubicin cytotoxic activity in A431/GR cells was examined
by MTT assay. Error bars in A and B denote s.e.m. (n=3).
*, p,0.05; **, p,0.01.
(DOC)
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Table S2 Association between membrane BCRP expres-
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Table S3 Association between membrane BCRP expres-
sion and patient’s demographic/clinical characteristics.
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